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generally been that off-pump surgery re-
sults in better neurocognitive outcomes
than on-pump procedures. Apart from the
well-documented role of cardiopulmonary
bypass in emboli generation, this finding
might be explained by the interesting fact
that it is actually the act of aortic cannula-
tion rather than the application of the clamp
itself that is likely to generate the greatest
number of emboli.5 This might explain the
better results in the off-pump group and the
comparable results in the 2 on-pump
groups with different degree of clamp use
in this trial, obviating the little additional
benefit of reduction in clamp number.
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Reply to the Editor:
The authors of our article thank Omer
Ashraf for his comments relating to our
published article. We thank him for his
careful reading and analysis.
Ashraf makes the comment that it was
invalid to compare the multiple clamping
group with the single clamping group and
the off-pump coronary artery bypass group
because the group is significantly older. As
we stated in the “Discussion” section, we
have performed additional analyses on pa-
tients in all 3 groups who were older than
the age of 65 years and found that the
multiple clamping group still had a statis-
tically greater number of neurocognitive
deficits at 3 and 6 months, thus invalidating
this criticism. There was no significant dif-
ference between the incidence of hyperlip-
idemia or atrial fibrillation in all 3 groups.
Relating to late neuropsychologic test-
ing, as mentioned by Ashraf, in our expe-
rience deficits that occur after 6 months
often appear in a new domain and thus
might represent a new brain lesion, usually
related to spontaneous atherosclerotic em-
boli.
Our analysis of the literature would sug-
gest that the question of better neurological
or neurpsychologic outcomes with OPCAB
surgery has evidenced no clear difference,
as did this study. Evidence from our insti-
tution would also suggest that the more
applications of aortic clamps, cannulas, or
proximal anastomoses, the greater number
of emboli. The temperature at which those
emboli reach the brain is also important in
determining outcome.
We thank Ashraf for his comments and
appreciate the time spent on the article.
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Redo coronary bypass grafting: Role
of arterial grafts and time interval
To the Editor:
I read with interest the article by Sabik and
colleagues wherein they present their experi-
ence with reoperations i n bypass surgery.1
Although the authors have conducted an
extensive temporal analysis, some impor-
tant concerns remain in reference to the
implications drawn from this report.
An important factor left unaddressed in
this study was the mean time for reopera-
tion. The time between primary and sec-
ondary bypass grafting is a determinant not
just of reoperation outcome but also of the
risk factors and patient characteristics
deeming reoperative therapy.2 Therefore it
is important to keep in consideration that
the risk factors for reoperation shown in
this report may not have uniform applica-
bility and may differ for patients undergo-
ing their second bypass at varying times
from their first surgery. The patency of
arterial and venous bypass conduits simi-
larly is likely to have individual alterations
at different points in time from the first
operation, illustrating the efficacy of arte-
rial grafts in reducing reoperation rate only
beyond a certain time interval from the
primary procedure.
The authors in this report, in cognizance
with certain trials in the past, advocate ex-
tensive use of arterial revascularization to
decrease reoperation rate on basis of their
findings. However, some amount of con-
flict prevails on this issue, with a number of
studies advocating no additional benefit of
using more than a single arterial graft.3,4 In
fact the reason that authors were unable to
document high reoperation rates among pa-
tients with multiple arterial grafts may be
owing to the notion that such patients are
more likely to undergo percutaneous angio-
plastic intervention rather than a second
bypass procedure. It is arguable, thus, that
broad use of arterial grafting would prevent
future myocardial ischemia in these pa-
tients. Even if a small extra degree of re-
operative risk was conferred by avoiding
use of more than 1 arterial graft, there
remains little overall clinical justification
for overuse of multiple arterial grafts,
bringing into view one of Dr Sabik’s own
recent reports that reoperation procedures
pose little extra patient hazards today.5
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More pumps—more questions
To the Editor:
We would like to congratulate Wilhelm
and colleagues1 on their outstanding results
concerning long-term survival after the im-
plantation of axial flow left ventricular as-
sist devices (LVADs). Since the worldwide
first implantation of the axial flow pump in
our institution on November 13, 1998,2 fol-
lowed by implantations in Vienna 1 week
later,3 these pumps have increasingly
gained acceptance. Long-term LVAD sup-
port not only enables patients to be bridged
to heart transplantation or recovery but also
opens up the opportunity to prolong high-
quality life for nontransplant candidates.
The article presented also shows that long-
term nonpulsatile or less-pulsatile blood
flow is not detrimental for the function of
the end organs. Our experience with 44
patients who were supported with rotary
blood pumps for more than 200 days ac-
cords with the results presented by the au-
thors. However, good long-term results can
also be achieved with pulsatile systems. Of
a total of 110 patients supported with an
LVAD for longer than 200 days in our
institution, 66 had pulsatile devices. Of
these, 3 patients were supported for more
than 4 years with the Novacor LVAS and 2
with the BerlinHeart Excor.4
During long-term support, appropriate
anticoagulation plays a key role for the
survival and complication rates. As antico-
agulative medication with the rotary
pumps, we now administer phenprocou-
mon with a target international normalized
ratio of 2.5, aspirin, and, in patients sup-
ported with axial flow pumps, additional
clopidogrel according to platelet aggrega-
tion tests, taking polymorphism of the
platelet GP IIb/IIIa receptors into consid-
eration.5 In our opinion the aspirin dose
should not exceed 100 mg/d.
We would be interested in the authors’
current anticoagulation protocols and whether
they used different regimens in patients
with different rotary blood pumps. Second,
based on the experience gained in Münster,
are there any preferences of pump type for
destination therapy?
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Reply to the Editor:
Left ventricular assist device (LVAD) sup-
port was originally used to bridge high risk
patients to heart transplantation.1 After in-
creased experience with this therapy
showed that the failing native heart may
have the potential to recover, LVAD ther-
apy provided the option of weaning se-
lected patients from mechanical support as
an alternative to transplantation.2 As tech-
nology made further progress, the duration
of support has increased markedly and
paved the way for destination therapy.
Device selection, however, in particular
for long-term support, still remains an un-
resolved question. Most centers have expe-
rience with one or two types of devices.
Devices are selected on the basis of per-
sonal experience. As long as people are
satisfied with the devices they are using,
they do not see a reason to change to other
systems. Only centers that handle large
numbers of patients use a variety of de-
vices, which offers them the opportunity to
compare systems. Prospective randomized
studies to evaluate different devices for
different indications have not yet been
performed.
It is of foremost importance that
LVADs meet the criteria of long-term reli-
ability and excellent quality of life in ad-
dition to the standard requirements of low
frequency of infection and thromboembo-
lism. The intracorporeal pulsatile devices
such as the Novacor LVAS and the Heart-
Mate I have demonstrated reliability for
long-term support.3,4 Extracorporeal pulsa-
tile devices such as the Thoratec LVAD
and the Berlin Heart Excor also have sup-
ported patients over the long term.5,6 The
introduction of axial-flow pumps revolu-
tionized mechanical circulatory support.
Pump size was markedly reduced, which
facilitated the implantation procedure.
Bleeding and infectious complications be-
came less frequent. Because axial-flow
pumps have not been on the market as long
as pulsatile devices, their long-term reli-
ability still has to be proved. Some patients
were supported for more than 1 year with
the DeBakey VAD, the Jarvik 2000, or the
Berlin Heart Incor, respectively.7-9 In par-
ticular, the Berlin Heart Incor promises
good long-term performance because of the
magnetic suspension of its impeller, which
provides virtually unlimited durability. The
longest support period with this device is
about 3 years. The design of axial-flow
pumps renders the exchange of single parts
less invasive than is required for larger
pulsatile devices.
Axial-flow pumps appear to provide a
better quality of life than pulsatile devices.
They are much smaller than intracorporeal
pulsatile pumps, which makes them easier
to implant in the pericardium. There is no
need for placement in the abdominal wall
or in the abdomen, which may cause gas-
trointestinal and digestive complications.
In addition, the axial-flow pumps run si-
lently, whereas the clatter of pulsatile de-
vices accompanies the patient and his en-
vironment day and night. Extracorporeal
pulsatile systems are associated with an
additional aesthetic and psychological dis-
advantage. The pump chambers, which are
located permanently outside the body, re-
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